3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
2
Phase 1/2
1
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
2
Interventions
Dexamethasone
169
Bortezomib
92
Lenalidomide
85
daratumumab
44
Thalidomide
44
pomalidomide
43
Melphalan
40
Cyclophosphamide
33
carfilzomib
29
Calcium Dobesilate
27
Prednisone
19
Doxorubicin
16
elotuzumab
14
isatuximab
12
Filgrastim
12
ixazomib
11
Vincristine
10
Peripheral Blood Stem Cell Transplantation
10
belantamab mafodotin
9
Granulocyte Colony-Stimulating Factor
9
Zoledronic Acid
8
selinexor
7
dexamethasone acetate
7
Epoetin Alfa
7
Etoposide
6
fludarabine
5
Cisplatin
5
Carmustine
5
iberdomide
4
Radiotherapy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Multiple Myeloma
×
melflufen
×
Clear all
NCT03151811
2024-01-30
OCEAN
Oncopeptides AB
Phase 3
Terminated
495 enrolled
15 charts
NCT04649060
2023-06-08
LIGHTHOUSE
Oncopeptides AB
Phase 3
Terminated
54 enrolled
21 charts